FIELD: medicine.
SUBSTANCE: group relates to the treatment and/or prevention of cancer, dependent on the natural AHR ligand. To this end, a therapeutically effective amount of an arylhydrocarbon receptor (AHR) inhibitor is administered.
EFFECT: possibility of effective treatment or prevention of a brain tumour, the pathogenesis of which is justified by unbalanced production of kynurenin.
15 cl, 24 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF USING AXL AS MARKER OF EPITHELIAL-MESENCHYMAL TRANSITION | 2010 |
|
RU2586493C2 |
| COMBINATION THERAPY AND METHOD FOR ASSESSING RESISTANCE TO TREATMENT | 2011 |
|
RU2587053C2 |
| ONCOLYTIC HERPES SIMPLEX VIRUSES TYPE 1 FOR TREATING BRAIN TUMOURS | 2021 |
|
RU2824514C1 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| INDUCTION OF APOPTOSIS IN TUMOUR CELLS, EXPRESSING TOLL-LIKE RECEPTOR | 2005 |
|
RU2401661C9 |
| METHOD FOR PRODUCING HIGH-FUNCTION THROMBOCYTES | 2016 |
|
RU2724533C2 |
| MODIFIED CELLS WITH CHIMERIC ANTIGEN RECEPTOR FOR TREATING CANCER EXPRESSING CLDN6 | 2020 |
|
RU2826058C2 |
| METHODS AND COMPOSITIONS FOR TREATING PERSISTENT INFECTIONS | 2006 |
|
RU2596491C2 |
| TREATMENT OF PROLIFERATIVE DISEASES WITH APPLICATION OF ANTISENSE OLIGOMER IAP AND CHEMOTHERAPEUTICAL PREPARATION | 2004 |
|
RU2376018C2 |
| USE OF ALPHAVIRUS IN PREPARATION OF ANTITUMOR DRUGS | 2015 |
|
RU2693938C2 |
